E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Familial Amyloid Polyneuropathy (FAP) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether diflunisal inhibits (peripheral and autonomic neuropathic) disease progression in patients with familial amyloid polyneuropathy (FAP). |
|
E.2.2 | Secondary objectives of the trial |
To examine TTR stability and amyloidogenicity in FAP subjects randomly assigned to the placebo and diflunisal treatment groups, correlating disease progression with TTR stability.
To compare the detection of FAP neurologic disease progression by a highly quantitative composite testing instrument (NIS + 7) versus a clinical neurologic scoring system (Kumamoto Scale).
To define the natural history of ATTR cardiomyopathy.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Biopsy proven amyloid deposition 2. Genotyping of variant TTR 3. Signs of mild to moderate peripheral or autonomic neuropathy -- detectable by a neurologist (performance status < 3) 4. Age > 18 and < 75 years 5. Negative bHCG testing and contraception for sexually active women of child-bearing potential
|
|
E.4 | Principal exclusion criteria |
1. Use of non-study NSAIDs within 30 days of enrollment 2. Other causes of sensorimotor polyneuropathy a. Vitamin B12 deficiency b. HIV patients on anti-retroviral drugs c. Diabetes mellitus (Hgb A1C > 6.2%) d. Chronic alcoholism (> 6 ounces hard liquor daily for 10 or greater years) 3. Co-morbidities with anticipated survival <2 years or liver transplantation in <1 yr 4. Liver transplantation 5. End-stage neuropathic disease (performance status > 3, parenteral nutrition, bedsores) 6. NYHA class IV (cardiac symptoms at rest & with minimal exertion) 7. Pregnancy or unwillingness to use contraception by women of childbearing age 8. Renal insufficiency (creatinine clearance < 30 ml/min) 9. Active or recent non-hemorrhoidal GI bleeding (within past 18 months) 10. Current anti-coagulation therapy, non-study NSAID or aspirin use 11. AST, ALT or Total Bilirubin > twice the upper limit of normal lab value 12. Non-steroidal or aspirin allergy/hypersensitivity 13. Thrombocytopenia (< 100,000 platelets/mm3) 14. Previous participation in this study 15. Inability or unwillingness of subject or legal guardian/representative to give written informed consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Neurologic Impairment Score (NIS+7), a highly quantitative assessment of peripheral neurologic function employed in studies of diabetic neuropathy, will be the primary outcome measure. NIS+7 is a composite score of neuropathic signs, 5 attributes of nerve conduction, quantitative sensation testing (vibration threshold), and autonomic function (heart rate variability).
Longitudinal studies of diabetic peripheral neuropathy demonstrate that a 2 point increase in mean NIS + 7 composite score correlates with clinically detectable progression of disease. In the Rochester Diabetic Neuropathy Study cohort, patients with diabetic polyneuropathy displayed an annual 0.85 point NIS + 7 score worsening. Neurologists and amyloid experts agree that the natural progression of FAP neuropathy is far more rapid than diabetic peripheral neuropathy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Drug administration will cease after 24 months of participation or if subjects: 1. exhibit study drug intolerance (GI bleed, hemolytic anemia, thrombocytopenia, hepatitis, renal insufficiency, hypersentivity reactions) 2. anticipate liver transplantation in <30 days 3. become pregnant despite using contraceptive agents 4. voluntarily withdraw.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |